| Name | Title | Contact Details |
|---|
Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. The company`s proprietary autologous fibroblast platform potentially allows for the development of personalized, targeted and redosable cell-based gene therapy product candidates for monogenic and chronic disorders. The company`s most advanced product candidate, dabocemagene autoficel (D-Fi), is currently being evaluated in a Phase 3 clinical trial for the localized treatment of chronic wounds due to recessive dystrophic epidermolysis bullosa (RDEB). The company is also currently evaluating FCX-013 in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma. In addition, Castle Creek Biosciences is pursuing discovery and potential development of early-stage novel product candidates with the goal of expanding its robust pipeline into other rare diseases and broader indications where there are significant unmet needs. The company operates an in-house, commercial-scale manufacturing facility in Exton, Pennsylvania that benefits from the validated systems and processes previously implemented at the site for manufacture of an FDA-approved cell therapy product. Castle Creek Biosciences, Inc. is a portfolio company of Paragon Biosciences, LLC.
Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions and is the leader in FDA-authorized prescription digital therapeutics.
Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology. Teewinot has also developed patent protected cannabinoid formulation technology all with the goal of improving human therapies. Headquartered in Tampa, Florida, Teewinot manufactures and licenses technology to make cost-effective and pharmaceutically pure cannabinoids. We are an industry leader in support of advancing medical research and product development. Teewinot`s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid-based medicines.
Octave is developing a comprehensive, first-in-class Care Management Platform.